Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of rat tissues surrounding Vcap xenograft tumors with chemical or physical denervation.

ABSTRACT: We propose that nerves play a trophic function for epithelium, not only during development, but also in adult homeostasis. Hence, nerves are likely key in cancer progression. Furthermore nerves are a functional regulator of prostate cancer genesis and progression to malignancy. A further understanding of the role of nerves in prostate cancer progression and a dissection of specific mechanisms would aid in identifying potential therapeutic targets that are centered on cancer-nerve interactions. To address this in detail, we have examined the effects of nerve function in the VCaP prostate cancer xenograft model and have elucidated differential gene expression profiles in this model.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE28717 | GEO | 2017/11/30

SECONDARY ACCESSION(S): PRJNA143063

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profiles of Vcap xenograft tumors with chemical or physical denervation.

Project description:Carcinoma VCaP tumors that evolve in denervated rat prostate glands exhibited a significantly altered gene expression profile and phenotype as compared with VCaP tumors that evolve in the normal, innervated rat prostate gland. Interestingly, unilateral denervation resulted in a reduction in tumor size relative to control and the reduction was more pronounced with botox (chemical denervation) as compared with MPG excision (physical denervation). Chemical and Physical denervation yield similar gene expression profiles.

2017-11-30 | GSE28716 | GEO

RNA sequencing analysis of VCaP cells resistant to abiraterone

Project description:Here, we analyze gene expression of prostate cancer cell line VCaP (VCaP WT) and VCaP after long time treatment with abiraterone (VCaP AA) in order to investigate possible resistance mechanisms to second-generation antiandrogens.

2024-06-30 | GSE196523 | GEO

Dexamethasone treatment of VCaP prostate cells

Project description:The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. We identified glucocorticoid receptor (GR) activity as modulator of enzalutamite sensitivity in the VCaP prostate cancer cell line. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance whereas a GR antagonist restored sensitivity. These expression profiling data demonstrate that GR transcriptional activity overlaps with that of AR in the VCAP model.

2013-12-27 | GSE51872 | GEO

RNA sequencing analysis of VCaP WT and VCaPrev cells

Project description:Here, we analyze gene expression of prostate cancer cell line VCaP (VCaP WT) and VCaP after testosterone boost (VCaPrev) in order to investigate the impact of the androgen axis on susceptibility to PCA treatments which are not directly AR-directed.

2020-12-31 | GSE159531 | GEO

Genes regulated by soluble guanylyl cyclase in VCaP prostate cancer cells

Project description:The aberrant activation of the ERG oncogenic pathway due to TMPRSS2-ERG gene fusions is the major driver of prostate cancer initiation and progression. We identified the alpha1 and beta1 subunits of soluble guanylyl cyclase (GUCY1A1, GUCY1B1) as major ERG-regulated genes in prostate cancer cells. Soluble guanylyl cyclase (sGC) is the major mediator of nitric oxide signaling in cells that, upon nitric oxide binding, catalyzes the synthesis of cGMP and subsequently activates PKG. We showed in ERG-positive PCa cells (VCaP) that cGMP synthesis was significantly elevated by ERG, leading to increased PKG activity and cell proliferation. To further understand the functions of sGC-cGMP pathway in prostate cancer cells, we performed RNA-seq analyses in VCaP cells to identify genes that are regulated by sGC.

2018-05-22 | GSE114738 | GEO

Dexamethasone treatment of VCaP prostate cells

2013-12-27 | E-GEOD-51872 | biostudies-arrayexpress

AR binding in prostate cancer cell lines VCaP and VCS2

Project description:This SuperSeries is composed of the following subset Series: GSE32344: Expression profilling of prostate cancer VCaP and VCS2 cells GSE32345: Genome-wide maps of AR binding in prostate cancer cell lines VCaP and VCS2 Refer to individual Series

2012-02-01 | E-GEOD-32356 | biostudies-arrayexpress

H3K4me1 and H3K27ac in Vcap cells

Project description:To understand the transcription regulation in prostate cancer cell line Vcap, we performed H3K4me1 and H3K27ac ChIP-seq with specific antibody.

2023-07-08 | GSE229871 | GEO

Expression profiling of human prostate VCaP and LNCaP cancer cells after silencing ERG or ETV1, respectively

Project description:Chromosomal rearrangements involving ETS factors, ERG and ETV1, occur frequently in prostate cancer. We here examine human prostate cancer cells control VCaP and LNCaP cells with ERG- or ETV1-silenced VCaP or LNCaP cells, respectively, in hormone deprived and stimulated conditions.

2013-03-01 | GSE39354 | GEO

ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes

Project description:Libraries of single-stranded oligodeoxynucleotides (ssODNs) can be enriched for sequences that specifically bind molecules on naïve complex biological samples like cells or tissues. Depending on the enrichment strategy, the ssODNs can identify molecules specifically associated with a defined biological condition, for example a pathological phenotype, and thus are potentially useful for biomarker discovery. We performed ADAPT, a variant of SELEX, on exosomes secreted by VCaP prostate cancer cells. A library of ~1011 ssODNs was enriched for those that bind to VCaP exosomes and discriminate them from exosomes derived from LNCaP prostate cancer cells. Next-generation sequencing (NGS) identified the best discriminating ssODNs, nine of which were resynthesized and their discriminatory ability confirmed by qPCR. Affinity purification with one of the sequences (Sequence 7) combined with LC-MS/MS identified its molecular target complex, whereof most proteins are part of or associated with the multiprotein ESCRT complex participating in exosome biogenesis. Within this complex, YBX1 was identified as the directly bound target protein. ADAPT thus is able to differentiate exosomes from cancer cell subtypes from the same lineage. The composition of ESCRT complexes in exosomes from VCaP versus LNCaP cells might constitute a discriminatory element between these prostate cancer subtypes.

2020-01-13 | PXD011496 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data